featured
De-Escalation of Radiotherapy After Primary Chemotherapy in cT1–2N1 Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study
Lancet Oncol 2022 Aug 08;[EPub Ahead of Print], SR de Wild, L de Munck, JM Simons, J Verloop, T van Dalen, PHM Elkhuizen, RMA Houben, AE van Leeuwen, SC Linn, RM Pijnappel, PMP Poortmans, LJA Strobbe, J Wesseling, AC Voogd, LJ BoersmaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.